Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011570 (
depression
)
172,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tissue plasminogen activator (tPA) is a serine protease involved in cleavage of neurotrophic factors. In addition, tPA and neuroserpin can also directly bind to low density lipoprotein receptor-related protein 1 (LRP1), promoting neurogenesis and neurite outgrowth. Given both the cleavage and non-cleavage actions of the fibrinolytic system are crucial in neurological functions, the present study, for the first time, systematically detected the changes of fibrinolytic system factors in rats exposed to chronic unpredictable mild stress (CUMS) or lipopolysaccharide (LPS) and patients with
depression
. In general, our data demonstrated that both CUMS and LPS reduced tPA but elevated plasminogen activator inhibitor-1 (PAI-1;
SERPINE1
) mRNA expression. Intriguingly, decreased expression of neuroserpin and LRP1 was also observed in rats exposed to CUMS or LPS. The down-regulated neuroserpin and LRP1 signaling were confirmed by western blotting and immunoflurence data. Likewise, elevated PAI-1 but a significant reduction of neuroserpin and LRP1 mRNA expression were observed in the peripheral blood mononuclear cells (PBMCs) of patients with first-episode
depression
, and the mRNA levels of PAI-1, neuroserpin and LRP1 were correlated with the Beck
Depression
inventory (BDI) scores, further strengthening the clinical significance and involvement of the fibrinolytic system in
depression
. Collectively, the present study demonstrated the alterations of fibrinolytic system in stressed and inflamed brain and in patients with first-episode
depression
, firstly showing that not only the cleavage actions, but also the non-cleavage actions of the system may play an essential role in the development of
depression
.
...
PMID:Altered fibrinolytic system in rat models of depression and patients with first-episode depression. 3141 44
Plasminogen activator inhibitor 1
(
PAI-1
), which is elevated in numerous disease states, has been implicated as a stress-related protein involved in the pathogenesis of
depression
. We measured
PAI-1
in the plasma of healthy and depressed individuals and assessed plasminogen activator (PA) expression and regulation by
PAI-1
in cultured normal human astrocytes (NHA). Elevated plasma
PAI-1
levels were found in depressed patients. Brain tissues from depressed individuals also showed stronger expression of hippocampal
PAI-1
by confocal imaging in comparison to healthy individuals. Using a lipopolysaccharide-induced inflammatory model of
depression
in mice, we measured
PAI-1
in murine plasma and brain, by ELISA and immunohistochemistry, respectively. Similar elevations were seen in plasma but not in brain homogenates of mice exposed to LPS. We further correlated the findings with depressive behavior. Ex vivo experiments with NHA treated with proinflammatory cytokines implicated in the pathogenesis of
depression
showed increased
PAI-1
expression. Furthermore, these studies suggest that urokinase-type plasminogen activator may serve as an astrocyte PA reservoir, able to promote cleavage of brain-derived neurotrophic factor (BDNF) during stress or inflammation. In summary, our findings confirm that derangements of
PAI-1
variably occur in the brain in association with the depressive phenotype. These derangements may impede the availability of active, mature (m)BDNF and thereby promote a depressive phenotype.
...
PMID:Increased expression of plasminogen activator inhibitor-1 (PAI-1) is associated with depression and depressive phenotype in C57Bl/6J mice. 3173 88
<< Previous
1
2
3